Molecular Diagnostics in Rheumatoid Arthritis (MODIRA) cohort: Validation of predictive tools for prognosis and treatment strategies in rheumatoid arthritis, a multi-centre cohort study

Molecular Diagnostics in Rheumatoid Arthritis (MODIRA) cohort: Validation of predictive tools for prognosis and treatment strategies in rheumatoid arthritis, a multi-centre cohort study - MODIRA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45651

Enrollment

100

Registered

2016-09-05

Start date

2017-06-01

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with established rheumatoid arthritis who are starting treatment with a biological (anti-TNFa, anti-IL-6,B cel inhibition or anti-costimulatory therapie)

Exclusion criteria

Exclusion criteria: patients with another rheumatological disease, that requires treatment with a biological

Design outcomes

Primary

Measure	Time frame
Validation of prognostic tests, based on serological, cellular and molecular markers, as well as several imaging techniques, to predict the response to treatment and to predict disease severity and joint damage	—

Secondary

Measure	Time frame
Cost effectiveness of (combinations of) in vitro tests in predicting response to biological treatment compared to existing tests such as RF and aCCP	—

Countries

Netherlands

Outcome results